MESOBLAST
Mesoblast is a developer of biologic products for the broad field of regenerative medicine. Mesoblast's patented Mesenchymal Precursor Cell (MPC) technology is being developed for an extensive range of major clinical diseases, including inflammatory and immunologic conditions of the joints and lungs, diabetes, and kidney disease, orthopedic spine conditions, and cardiovascular disorders.
MESOBLAST
Industry:
Biotechnology Health Care Health Diagnostics
Founded:
2004-01-01
Address:
Melbourne, Victoria, Australia
Country:
Australia
Website Url:
http://www.mesoblast.com
Total Employee:
51+
Status:
Active
Contact:
(212) 880-2060
Email Addresses:
[email protected]
Total Funding:
412.3 M USD
Technology used in webpage:
SPF Domain Not Resolving Euro Microsoft Exchange Online Office 365 Mail IPv6 Microsoft Azure DNS Cloudflare Hosting IIS Cloudflare DNS
Similar Organizations
Lucira Health
Lucira Health is a biotechnology company that offers disposable test kits to detect RNA and DNA of infectious diseases.
FORMA Therapeutics
FORMA Therapeutics is a biopharmaceutical company focused on the discovery, development, and commercialization of transformative medicines.
Human Longevity
Human Longevity is a genomic-based, health intelligence company empowering proactive healthcare and enabling a life better lived.
Radius Health
Radius Health develops drug therapies for osteoporosis and women’s health.
Soligenix
Soligenix is a biopharmaceutical company that develops biodefense vaccines and therapeutics to treat rare diseases.
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2010-05-12 | Angioblast Systems | Angioblast Systems acquired by Mesoblast | N/A |
Investors List
Hercules Capital
Hercules Capital investment in Post-IPO Debt - Mesoblast
Novaquest Capital Management
Novaquest Capital Management investment in Post-IPO Equity - Mesoblast
Australian Government for Research & Development
Australian Government for Research & Development investment in Post-IPO Equity - Mesoblast
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2014-04-09 | Osiris Therapeutics | Mesoblast investment in Post-IPO Equity - Osiris Therapeutics | 15 M USD |
Key Employee Changes
| Date | New article |
|---|---|
| 2022-02-01 | Mesoblast Appoints Dr. Eric Rose as Chief Medical Officer |
Official Site Inspections
http://www.mesoblast.com Semrush global rank: 3.77 M Semrush visits lastest month: 3.58 K
- Host name: 104.19.220.104
- IP address: 104.19.220.104
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
